WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2015042229) TRANSGLUTAMINASE 4 AS A PROSTATE SPECIFIC AUTOANTIGEN AND THE METHODS OF USE THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2015/042229    International Application No.:    PCT/US2014/056239
Publication Date: 26.03.2015 International Filing Date: 18.09.2014
IPC:
A61K 39/00 (2006.01), A61K 39/395 (2006.01), G01N 33/567 (2006.01), C07K 14/00 (2006.01), A61K 38/00 (2006.01)
Applicants: LANDEGREN, Nils [SE/SE]; (SE).
KAMPE, Olof [SE/SE]; (SE).
SNYDER, Michael [US/US]; (US).
SHARON, Donald [US/US]; (US)
Inventors: LANDEGREN, Nils; (SE).
KAMPE, Olof; (SE).
SNYDER, Michael; (US).
SHARON, Donald; (US)
Agent: HIGHLANDER, Steven, L.; (US)
Priority Data:
61/880,590 20.09.2013 US
Title (EN) TRANSGLUTAMINASE 4 AS A PROSTATE SPECIFIC AUTOANTIGEN AND THE METHODS OF USE THEREOF
(FR) NOUVEL AUTO-ANTIGÈNE
Abstract: front page image
(EN)The disclosure relates to transglutaminase 4 as a prostate specific autoantigen, and methods for diagnosis of autoimmune polyendocrune syndrome type 1, autoimmune prostatitis in autoimmune polyendocrine syndrome type 1, and isolated autoimmune prostatitis. The disclosure further relates to use of transglutaminase 4 and transglutaminase 4 antibodies and antibody conjugates for the treatment of prostate cancers.
(FR)La présente invention concerne la transglutaminase, (4) comme nouvel auto-antigène spécifique de la prostate, et des méthodes pour le diagnostic du syndrome polyendocrinien auto-immun de type 1, la prostatite auto-immune dans le syndrome polyendocrinien auto-immun de type 1 isolé, et la prostatite auto-immune. L'invention concerne, en outre, l'utilisation de transglutaminase (4) et d'anticorps et de conjugués d'anticorps de transglutaminase (4) pour le traitement des cancers de la prostate.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)